Targeting the engine room of the cancer cell
The study by Dr. Andrea Califano of Columbia University Irving Medical Center and Dr. Irvin Modlin of Yale University and Wren Laboratories LLC, co-senior author on the study, with collaborators from 17 research centers worldwide, details a proof of concept for a novel analytical platform applicable to any cancer type and validates its predictions on gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The latter represent a rare class of tumors of the digestive system that, when metastatic, are associated with poor survival.
In a comprehensive analysis of samples from 212 patients, the team first identified a new class of drug-targets, called master regulators, which are rarely if ever mutated in cancer patients, and then predicted the drugs that can specifically invert their activity. Surprisingly, even though tumors were analyzed on an individual patient basis, the algorithm predicted the same top drug - Entinostat - for almost half of the metastatic patients. More importantly, when tested in a xenograft transplant of the tumor in a mouse, this drug induced dramatic shrinking of the tumor, while drugs predicted to have partial or no effect were also validated to produce results in line with predictions. These data led to rapid IND (Investigational New Drug) approval by the FDA for a metastatic GEP-NET clinical trial that is open and recruiting patients at Columbia University.
The innovative approach proposed in this manuscript, OncoTreat, is now available as a New York State Department of Health approved test through the Department of Pathology and Cell Biology at CUIMC. The test was co-developed with DarwinHealth, a precision oncology company born out of the Califano Lab work. It is the only such test designed to predict drugs that are optimally matched to individual patient tumors for 10 different aggressive tumor subtypes of ovarian, breast, pancreas, prostate, bladder, and lung cancer, as well as meningioma, sarcoma, glioblastoma, and GEP-NETs.
"This manuscript represents a first proof of concept of what may become a valuable new tool to deliver an effective and systematic precision medicine approach to cancer patients that may complement what we are currently doing with genetic mutations," says Dr. Califano, the Clyde and Helen Wu Professor of Chemical and Systems Biology and chair of the Department of Systems Biology at CUIMC.
"Using novel systems biology methodologies, which combine the use of supercomputers with large-scale pharmacological assays, we can computationally predict and prioritize drugs and drug combinations that will most effectively kill cancer cells," explains Dr. Califano. "Such an approach is especially promising for patients with aggressive tumors, who lack actionable mutations, fail to respond to targeted inhibitors or immune-checkpoint inhibitors, or relapse following initial response to a standard of care drug or drug combination. These patients, who unfortunately represent the majority of the aggressive tumor cases, present few, if any, effective therapeutic options. We hope that OncoTreat may offer the oncologist new alternatives when they run out of approved therapies, alternatives that are predicated on an increasingly mechanistic understanding of cancer cell regulation and response to drugs rather than on educated guesswork."
Dr. Modlin, who had initially proposed the concept of addressing Neuroendocrine tumors using the innovative strategy developed by Dr. Califano, commented that the successful demonstration of the efficacy of a pre-treatment molecular identification strategy was a significant advance on previous practice where treatment agents were used based upon serendipitous selection rather than objective molecular evidence. This work combined with the use of molecular signature tools in blood to monitor real-time efficacy of therapy on disease are likely to change the face of therapeutic management in many diseases.
OncoTreat's precision medicine approach
The OncoTreat framework centers on identifying and analyzing actionable proteins in cancer patients, independent of their genetic mutations. Called master regulators (MR), these proteins are organized into small regulatory modules - so-called tumor checkpoints - which are responsible for regulating and ensuring the stability of tumor cells. Master regulators and tumor checkpoints can be efficiently and systematically elucidated using the VIPER algorithm developed by the Califano Lab; critically, these analyses allow tracking their activity through metastatic progression, relapse, and development of drug resistance. These computational models were built based on mathematical concepts from information theory and Bayesian statistics and have been extensively validated over the past decade.
MR proteins represent a novel class of tumor vulnerabilities and potential therapeutic targets that are being increasingly adopted by pharmaceutical companies. Extensive research has demonstrated that shutting down the activity of these proteins is catastrophic for tumor cells, making it virtually impossible for them to survive and grow in their environment. In this study, drug compounds are prioritized based on their ability to revert the coordinated activity of 50 such master regulator proteins, as identified by the analysis of tumor samples. Predicted activity reversal was surveyed from an analysis of drug assays both in cell lines and in vivo, in PDX (Patient-Derived Xenografts) mice models.
"Master regulators--a new Achilles' heel of cancer--represent the engine room of the cancer cell, where the effects of all tumorigenic mutations come together. What OncoTreat is able to do is attack this convergence point with a therapeutic intervention," says collaborator Gary Schwartz, MD, division chief of hematology and oncology at CUIMC and associate director of the Herbert Irving Comprehensive Cancer Center. "By collapsing this tumor bottleneck, blocking this Achilles' heel, the cancer can no longer survive. This method is so innovative, requiring a lot of mathematical modeling and understanding. It's a whole new approach to cancer therapeutics, taking us in an entirely new direction."
Califano and team validated the OncoTreat approach on a cohort of 212 gastroenteropancreatic neuroendocrine tumors, a deliberate choice since GEP-NETs are rare and poorly characterized, making them one of the more challenging tumors to research. Their analysis identified several MR proteins, including key immune function modulators, whose role as critical tumor dependencies was experimentally confirmed. The GEP-NET cells were screened against a library of 107 compounds, and found that the drug, Entinostat, proved to successfully invert the activity of the top 50 MR proteins in 42 percent of GEP-NET patients, providing the rationale for the follow up clinical trial.
"It is certainly our hope that this may provide a short cut to identify viable candidates for phase 2 trials in this and other malignancies," says coauthor Edward Gelmann, MD, professor of medicine and of pathology and cell biology at CUIMC.
In addition to its potential therapeutic value, OncoTreat provides novel insight into the mechanisms and maintenance of GEP-NETs. In future work, Califano and collaborators intend to expand this approach to cover more than 80% of human malignancies and to develop clinical trials that will test the predictions in patients.
Other news from the department science
Revolutionary cell therapy: rebooting the immune system stops autoimmune diseases
Single infusion of CAR-T cells replaces immunosuppressive drugs
Cracking the Code of Neurodegeneration: New Model Identifies Potential Therapeutic Target
Novel neural cell culture model developed
IQ does not remain the same throughout life
A meta-study shows that an intelligence quotient measured once is not necessarily meaningful later on
New mechanism for regulating cell division in the bacterial pathogen Klebsiella uncovered
Small ribonucleic acid with a big impact
More brain than trait: Decoding the neural pathways of curiosity
Discovery sheds new light on the biological basis of human curiosity and could have far-reaching implications for the understanding and treatment of diseases
What Our Genetic Information Tells Us About Type 2 Diabetes Risk and Complications
Largest Study on Genetic Risk for Diabetes Now Published
Study Proposes Framework to Standardize Biomarkers of Aging and Accelerate Clinical Use
Improving the life expectancy and health of the population
Researchers succeeded in biomanufacturing using chemically synthesized sugar for the first time in the world
Biomanufacturing using chemically synthesized sugars enables sustainable supply of sugar without competing with food
What can bulls tell us about men?
Towards a better understanding: Which genes and mechanisms control male fertility?
µkiss-and-tell: A new method for precision delivery of nanoparticles and small molecules to individual cells
"Like a paintbrush", easy and cost-effective to use
How COVID-19 affects the brain
Neurological symptoms apparently not a result of SARS-CoV-2 infection of the brain
Microscopy: Overcoming the traditional resolution limit for the fast co-tracking of molecules
Researchers have developed an innovative method to simultaneously track rapid dynamic processes of multiple molecules at the molecular scale
Shredding to plan – protein recycling for immune defense
“If we know how the proteasome generates immunopeptides, we can predict peptide splicing. In future, these predictions could, in turn, help develop novel vaccines against cancer or infectious diseases”
New nanosensors make diagnostic procedures more sensitive
The nanosensors can be used to track reactions with invisible light, saving materials and time
Most read news
mRNA therapeutic successfully combats ovarian cancer
The mRNA therapeutic successfully combated cancerous cells and tumors in vitro as well as metastases in mice
The secret of whales: How giant whales defy cancer
Study of gigantism in whales provides clues to genomic mechanism involved in tumor suppression
A virus that kills sleepers
Researchers have found a virus that kills dormant bacteria: This rare discovery could help to combat germs that can’t be treated with antibiotics alone
Microbe of the Year 2023: Bacillus subtilis – for health and technology
Already, Bacillus subtilis is indispensable in many industries, and many more innovations are expected
Making Ends Meet: Researchers Find That a Protein Superglue is Crucial for DNA Damage Repair
New Understanding for Cancer Treatments
A standard blood test can predict a heart attack
Using the results of a standard blood test and an online tool, you can find out if you are at increased risk of having a heart attack within six months
Learning from Nature: How a fungus makes a hard job easier
Researchers analyze a fungal biosynthetic pathway and discover a capable enzyme
Innovative microscopy technique reveals secrets of lipid synthesis inside cells
Two-color infrared photothermal microscopy (2C-IPM) opens new avenues for long-term study of lipid metabolism in living cells
New agent blocks stress response
In the future, this could enable stress-related conditions such as chronic depression to be treated much more specifically and with fewer side effects
Artificial cartilage with the help of 3D printing
New approach to producing artificial tissue works with cells in microstructures from the 3D printer
Destroying Tumor Cells with Calcium
Activating calcium channels leads to a deadly influx of calcium ions into tumor cells
More news from our other portals
Battery start-up is developing safe, long-lasting thin-film solid-state batteries that can be charged and discharged in one minute
BTRY raises CHF 900,000 in pre-seed funding for the development of an innovative solid-state battery
Mystery of Novel Clove-Like Off-Flavor in Orange Juice Solved
Tracking down off-flavours using techniques such as gas chromatography-olfactometry and aroma extract dilution analysis
World first: The first CO2-negative biofuel comes from Germany
Start-up Carbon Farming Germany revolutionizes fuel production with BeyondZero
Planned EU legislation on packaging threatens popular seasonal confectionery
Federal Association of the German Confectionery Industry fears the end of chocolate Easter bunnies & Co.
Chemists are on the hunt for the other 99 percent
New mass spectrometry combo offers promise for tapping nature’s unknown chemical universe
Green steel from toxic red mud
An economical process with green hydrogen can be used to extract CO2-free iron from the red mud generated in aluminium production
BASF and Envision Energy enter a collaboration to drive sustainable energy solutions
Collaboration to accelerate conversion of green hydrogen and CO2 to e-methanol
Eckes-Granini further expands important out-of-home business segment
Market share gains and double-digit sales growth in 2023
GPT-3 for chemical research
Researchers develop fast and user-friendly language model for chemical tasks
Microgreens made to order
Italian scientists have tailored iodine and potassium content of radishes, peas, rocket and chard
Revolutionizing batteries: Coffee grounds power high-performance sodium-ion anodes
Using coffee waste as a precursor material for hard carbon synthesis
Greetings from the island of enhanced stability: The quest for the limit of the periodic table
A fresh view on new superheavy elements
Detect 'forever chemicals' in under 3 minutes
New lab-based method to detect traces of PFAS from food packaging material, water and soil samples